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Objectives.To perform a 6-week double-blind RCT in Raynaud’s phenomenon (RP) comparing the plant extract St. John’s Wort
(SJW) to placebo. Methods. RP patients having at least 7 attacks per week were stratiﬁed by primary and secondary RP and within
secondary by systemic sclerosis or other connective tissue disease. Subjects completed a daily standardized diary recording all RP
attacks (frequency, duration and severity). Serum levels of 18 inﬂammatory and angiogenic cytokines were measured pre- and
post-treatment. Results. Eighteen patients completed the study; 8 received SJW and 10 placebo. The decrease in mean number of
attacksperdaywas0.75withSJWand1.01withplacebo,P = 0.06.Attackdurationandseveritywerenotdiﬀerentbetweengroups.
Cytokine analyses demonstrated no between-groups diﬀerences. Combining treatment groups, those with >50% improvement in
frequency of attacks yielded a signiﬁcant increase in E-selectin (P = 0.049), MMP-9 (P = 0.011), G-CSF (P = 0.02), and VEGF
(P = 0.012) pre- versus post-treatment. A ≥50% improvement in severity of attacks corresponded to a signiﬁcant increase in
levels of sVCAM-1 (P = 0.003), sICAM-1 (P = 0.007), and MCP-1 (P = 0.004). Conclusions. There were no clinical or biomarker
beneﬁt of SJW versus placebo in RP. However, combining all patients, there were changes in some cytokines that may be further
investigated.
1.Introduction
Raynaud’s phenomenon (RP) aﬀects 3–5% of the popu-
lation [1] and is characterized by episodic vasospasm of
digital arteries causing pallor, cyanosis, and/or rubor upon
rewarming. It is caused by poor blood ﬂow to digits, often
occurring with cold exposure and stress. The severity of
symptoms ranges from mild to severe pain, and in secondary
RP there may be ischemic complications. RP can be primary
(idiopathic)orsecondary.SecondaryRPisassociatedwithan
underlying disease (often a connective tissue disease {CTD}
suchassystemicsclerosis {SSc, scleroderma},systemiclupus
erythematosus {SLE}, and Sjogren’s syndrome).
The exact mechanisms causing RP are unknown, but
inﬂammatory and angiogenic cytokines secreted by cir-
culating cells and endothelial cells (ECs) may stimulate
vascular abnormalities that ultimately reduce blood ﬂow.
Underlyingendothelialdysfunctionlikelyinitiatesandmedi-
ates this pathological process [2]. ECs in RP promote
an inﬂammatory response through elevated production of
proinﬂammatory cytokines [2] and increased expression of2 ISRN Rheumatology
adhesion molecules [3, 4] and secretion of vasoconstric-
tor and proﬁbrotic mediators, such as endothelin-1 and
angiotensin, instead of vasodilators [5].
Primary RP is most often controlled with lifestyle
changes (keeping warm, smoking cessation), whereas sec-
ondary RP in patients with SSc frequently requires systemic
treatment. Depending on disease severity, the choice of
medication includes calcium channel blockers (CCBs), such
as nifedipine, and other vasodilators. CCBs in both primary
andsecondaryRaynaud’shavedemonstratedmodestbeneﬁt;
however these medications frequently have side eﬀects such
as hypotension, ﬂushing, peripheral edema, and headaches
[6–8] .T h e r ei sa nu n m e tn e e df o ra ne ﬀective and well-
tolerated treatment in moderate-to-severe RP.
One trial suggested that ﬂuoxetine (an antidepressant)
was eﬀective in the treatment of both primary and secondary
RP [9]. Fluoxetine is a selective serotonin reuptake inhibitor
(SSRI) which in RP may be improving vascular endothelium
[9]. Ketanserin, a selective antagonist of serotonin, has also
b e e ns t u d i e di nR P[ 10] .S e r o t o n i nr e c e p t o r sh a v eb e e n
shown to be important in vasospasm in patients with RP
[11].St.John’sWort(SJW,hypericumperforatum)isanatural
herbal product with some SSRI-like properties. In mild-to-
moderate depression, SJW appears to be equally eﬀective,
with fewer side eﬀects than prescription SSRI drugs [12–
17]. Thus, SJW may be an eﬀective, safe, and well-tolerated
alternative treatment for RP via eﬀects on serotonin. In this
study, the dose of SJW was selected to be 600mg a day (given
as 300mg BID). Depression trials have dosed SJW from 300
to as high as 900mg BID [12–17], where 300mg BID was
superior to placebo and well tolerated [16, 17].
We performed a trial with SJW in subjects with primary
and secondary RP. The hypothesis of this trial was that SJW
w o u l db em o r ee ﬀective than placebo in the treatment of RP,
as deﬁned by decreased frequency, duration, and severity of
attacks.
2. Methods
2.1. Study Design. This randomized, double-blinded,
placebo-controlled trial was registered at clinicaltrials.gov.ca.
It was approved by Health Canada (in the Natural Health
Product division). Ethics approval was obtained from the
University of Western Ontario Ethics Committee.
2.2. Subjects. Subjects were recruited from a rheumatology
clinic over two winters, as Raynaud’s symptoms are more
severe at this time. All subjects had symptomatic RP and
were stratiﬁed by primary versus secondary Raynaud’s, and
within secondary RP between systemic sclerosis and other
connective tissue diseases. Inclusion criteria were primary
or secondary RP as diagnosed by a rheumatologist, clinical
need for treatment of RP with at least 7 attacks per week
over a two-week run in, age at least 16 years, able to
provide informed consent, and ability to complete the daily
standardizedRPsymptomdiarypriortorandomization.The
exclusion criteria consisted of a prior allergic reaction to
SJW, depression requiring treatment, use of SSRIs or other
antidepressants with the exception of low-dose amitriptyline
usedforreasonsotherthandepression,useofdrugsthatmay
interact with SSRIs such as cyclosporine, warfarin, digoxin,
and theophylline, clinically signiﬁcant noncompliance, and
anticipated need for surgery (sympathectomy) within 3
months of the trial. Subjects that met these criteria were
randomized using computer-based randomization 1:1 to
receive either SJW dosed at 300mg twice daily (BID)
or a lactose placebo BID for 6 weeks. St. John’s Wort
(SJW) was provided by Webber Pharmaceuticals. SJW was
reencapsulated by our research pharmacists who also made
the encapsulated placebo. Subjects completed a daily journal
with standardized questions about each attack (severity and
duration).Usingthediary,thenumberofattacksperdaywas
calculated. They also recorded any potential adverse events
(AEs). Every 2 weeks subjects were seen by a study nurse and
asked about side eﬀects and digital ulcers, and patient global
assessments were performed.
Blood was drawn into EDTA tubes at 0 and 6 weeks post-
treatment,immediatelyspun,andplasmafrozenat-80◦Cfor
later analysis of 18 inﬂammatory and angiogenic cytokines
using multiplexed immunoassays (Millipore Corp., MA) and
ELISA for TGF-β1 (BD Biosciences, NJ).
2.3. Eﬃcacy Measures. Primary outcome measures were the
frequency of RP (number of attacks daily), severity of RP on
a 0 to 10 scale, duration of RP attacks (in minutes) (from
the RP diary), and changes in the levels of inﬂammatory
and angiogenic cytokines between baseline and 6 weeks
post-treatment. Secondary outcome measures assessed at the
beginning and end of the treatment period were the health
assessment questionnaire (HAQ) disability index, patient
global assessment of RP, and the presence and location of
digital ulcers.
2.4. Sample Size Calculation. Using a between-group diﬀer-
ence in number of RP attacks at the end of the study of 2.4
attacks per day in placebo and a 45% reduction in attacks in
SJW, and assuming an equal SD of 0.75 with 80% power and
a two-sided P v a l u eo f0 . 0 5 ,w ew o u l dn e e do n l y8p a t i e n t s
per group to complete the study. This was an early phase
study (the ﬁrst of SJW in RP), and the data were to direct
future potential RP trials with SJW.
2.5. Statistics. Between-group comparisons (SJW compared
to placebo) were done using 2-tailed, paired t-tests to
analyze for signiﬁcant changes (fold changes) in cytokine
levels between baseline and 6 weeks post-treatment. Similar
analyses were then performed combining all completers
based on patient-reported improvement (≥ or <50%) in the
frequency and severity of attacks, irrespective of treatment
allocation, to ﬁnd a correlation between cytokines and
symptoms. Within-group comparisons were done using
paired t-tests in completers to analyze for signiﬁcant changes
in the frequency, duration, and severity of attacks per day.ISRN Rheumatology 3
3. Results
3.1. Subjects. Thirty-three patients with symptomatic RP
were screened (30 females, 3 males) and 25 were randomized
(as ﬁve had <7 attacks per week over the two week run in
and three did not want to continue in the study). In those
randomized, 5 had primary RP and 20 had secondary RP,
of whom 11 had SSc and 2 were undiﬀerentiated CTD, 2
SLE, 2 RA, and one each of mixed connective tissue disease,
Sjogren’s syndrome, and dermatomyositis. Eighteen subjects
completedthetrial(2hadprimaryRPand8withSSc),with8
on active SJW and 10 on placebo. Adverse events (AEs) were
common (57% SJW, 43% placebo), especially headaches.
While these AEs were generally mild, there was one serious
AE in a subject with secondary RP and scleroderma that
involved hospitalization due to atrial ﬁbrillation. Seven who
were randomized dropped out, 4 due to AEs (3 on SJW
and one on placebo). There were no signiﬁcant diﬀerences
between SJW and placebo using ITT and also comparing
only the completers.
3.2. Severity, Duration, and Frequency of Attacks. There
were no signiﬁcant diﬀerences in the severity, duration or
frequency of attacks between the groups. However, there
were signiﬁcant within-group diﬀerences observed from
beginning to end of the trial in both SJW and placebo groups
(Table 1 shows the completers only analysis). There were
no important diﬀerences for the secondary endpoints when
comparing SJW to placebo.
The within-group pre- and post-treatment frequency
and severity of attacks were not signiﬁcant in the SJW group.
In contrast, within the placebo group, the frequency of
attacks per day decreased signiﬁcantly (P = 0.001) as did
the severity of attacks (P = 0.004). The duration of daily
RP attacks decreased signiﬁcantly with SJW (P = 0.002)
and also with placebo (P = 0.009). The absolute change
was numerically less with SJW than placebo. This diﬀerence
in duration of attacks was further analyzed within the SJW
group by the subtype of secondary RP (SSc and other CTD),
but not in primary RP as the number of participants was
too small. These analyses showed a signiﬁcant improvement
(P = 0.033) in the duration of attacks in subjects with
secondary RP in the nonscleroderma group.
3.3. Cytokines. There were no signiﬁcant changes in cytokine
levels from pre- to post-treatment between the SJW and
placebo. All patients who completed the study were collated
(combining SJW and placebo) based on patient-reported
scores into ≥ or <50% improvement in the frequency
and then severity of RP attacks to analyze the signiﬁcance
between cytokines and symptoms, irrespective of treatment
allocation. Cytokines were analyzed as the percent change
relative to baseline and also as mean diﬀerences between the
start and end of treatment since both types of analyses may
have biological relevance.
3.4. Percent Change. We found that those with a >50%
improvement in patient-reported frequency of attacks was
signiﬁcantly associated with a larger fold increase in levels
of MMP-9 (P = 0.027), MIP-1β (P = 0.045), and VEGF
(P = 0.002) between baseline and the end of treatment when
compared to a <50% improvement (data not shown). There
wasno signiﬁcantcorrelationbetween severity ofattacks and
percent change in cytokine levels.
3.5. Mean Diﬀerences. Comparing subjects who improved
by at least 50% to those who did not with respect to the
frequency of RP attacks demonstrated signiﬁcant changes
in E-selectin (P = 0.049), MMP-9 (P = 0.011), G-CSF
(P = 0.02), and VEGF (P = 0.012) (Table 2). Using the
same comparison for ≥ or <50% improvement in severity
of attacks, a signiﬁcant increase in sVCAM-1 (P = 0.003),
sICAM-1 (P = 0.007), and MCP-1 (P = 0.004) was observed
(Table 3).
4. Discussion
SJW was not superior to placebo, and in fact, placebo was
numerically but not signiﬁcantly better than SJW on some
outcomes. It is likely that shared properties between SSRIs
and SJW in the treatment of depression are not similar in
RP treatment at the dose studied [9]. SJW should not be
pursued for the treatment of RP in a larger trial as there
was no biomarker or clinical change that was superior to the
placebo group.
Thereweresigniﬁcantwithin-groupresultswhichunder-
scores that any open-label treatment trial needs to be
interpreted with caution in RP as there is likely a large
placebo eﬀect or regression to the mean. Even proof-of-
concept trials testing new agents in RP should have a double-
blinded, randomized trial design.
Therearemultiplepotentialreasonswhythisisanegative
trial which could include ineﬃcacy of SJW, underdosing,
heterogeneity of the patients, small sample size, inadequate
outcome measurements, or spurious results, but there was
not even a trend of improvement compared to placebo.
Manypublishedtrialshavecombinedprimaryandsecondary
RP stratifying by type of RP, which we did. We tried to
have a more homogenous group of patients to study by
using only patients with a high frequency of RP attacks.
Also, the majority of patients were secondary RP, so perhaps
they are more diﬃcult to treat than primary RP, and in
this group the numbers are incredibly small to make any
treatment conclusion within this small subset of completers.
The SJW dose was at the lower end of what has been used
for depression trials but nevertheless the dose we chose had
demonstrated eﬃcacy [16, 17]. The Raynaud’s Condition
Score (a daily self-assessment questionnaire of RP on an
ordinal scale) [18] was not collected within the diaries but at
each visit patient global RP assessment was done. Biomarker
data also did not demonstrate that SJW is eﬀective in RP.
Some biomarkers improved in patients whose RP was better,
but they did not improve more in the SJW group compared
to placebo. The placebo changes for RP outcomes in this
study may have occurred as there is often regression to the
mean in RP trials. For instance, when patients enroll in
RP trials requiring a large number of attacks, they enter at
a high level of RP activity which may decrease over time,4 ISRN Rheumatology
Table 1: Within-group characteristics for frequency, duration, and severity of RP in SJW compared to placebo in the completers. There were
no between-group diﬀerences.
Baseline SJW
(N = 8)
6-Week
Followup
SJW
Mean
diﬀerence
SJW
P-value
Within group
SJW
Baseline
Placebo
(N = 10)
6-Week
Followup
Placebo
Mean
diﬀerence
Placebo
P-value
Within group
Placebo
Frequency (mean
no. of attacks per
day)
3.175 2.4238 .7513 0.1238 2.366 1.353 1.0130 0.001
Duration (mean
total of attacks in
minutes per day)
28.279 18.009 10.2703 0.0019 26.010 13.510 12.4992 0.009
Severity (scale 0 to
10) 4.752 3.785 .9668 0.0758 2.954 1.947 1.0066 0.004
Table 2: Within-group comparisons of patient-reported improvements in the frequency of Raynaud’s attacks and the diﬀerence of cytokine
levels between pre- and post-treatment. P values were calculated using 2-tailed, paired t-tests. Data represents mean comparisons of changes
in cytokines in those who had more than 50% reduction in frequency (number) of RP attacks compared to those who did not.
Cytokine Mean cytokine change Diﬀerence Std. error diﬀerence P value
Frequency of attacks
improved by ≥50%
(n = 7)
Frequency of attacks
improved by <50%
(n = 6)
sE-Selectin 5843.8 −3473.3 9317.1 4203.1 0.049
sVCAM-1 134550.6 −14819.9 149370.5 122138.5 0.247
sICAM-1 8861.6 −13292.5 22154.1 17813.4 0.239
MMP-9 68574.0 −104997.8 173571.8 57260.1 0.011
tPAI-1 −188.4 −10086.1 9897.7 7392.6 0.208
IL-4 −0.2 0.0 −0.2 0.2 0.356
IL-6 −2.6 0.1 −2.7 2.9 0.387
IL-8 −0.4 −1.1 0.7 1.9 0.726
IL-10 0.0 0.0
IL-12p70 0.3 0.1 0.3 0.3 0.416
IL-17 0.0 −0.5 0.5 0.5 0.363
Eotaxin −4.6 0.6 −5.2 9.4 0.588
Basic FGF 1.0 3.4 −2.5 2.9 0.408
G-CSF 15.0 −12.1 27.0 10.0 0.020
IFN-γ −13.6 0.6 −14.1 21.8 0.531
IP-10 110.1 78.9 31.2 106.8 0.776
MCP-1 −12.4 −3.1 −9.3 20.2 0.654
MIP-1α −0.4 0.3 −0.7 0.5 0.199
MIP-1β 7.1 −3.5 10.6 5.5 0.082
PDGF-BB −133.4 −244.1 110.7 309.2 0.727
TNF- α −1.0 2.2 −3.2 3.1 0.341
VEGF 7.3 −11.5 18.8 6.3 0.012
TGF-β1 −2.4 −4.1 1.7 2.9 0.565
and attacks are often related to cold temperature, which
may vary over the study as a 6-week long trial started in
winter may ﬁnish for some patients in spring. However,
we cannot infer that SJW was worse than placebo as there
were no statistically signiﬁcant between-group diﬀerences
and in both allocations there was improvement of RP. The
study is too small to comment on individual background
medications but patients were in a steady state if they were
using calcium channel blockers or losartan for RP. We did
notstopapartiallyeﬀectivedrugduetotheethicsofstopping
treatment during winter in patients with more than 7 attacks
per week on their current treatment if it was perceived to
have partial beneﬁt. We did not ﬁnd lack of tolerability with
otherRPmedicationswhenaddingSJW,butthenumbersare
too small. SJW does have many potential drug interactions
but the Health Canada-approved protocol excluded onlyISRN Rheumatology 5
Table 3: Within-group comparisons of patient-reported improvements in the severity of Raynaud’s attacks and the diﬀerence of cytokine
levels between pre- and post-treatment. P values were calculated using 2-tailed, paired t-tests.
Cytokine Mean cytokine change Mean diﬀerence Std. error diﬀerence P value
Severity of attacks
improved by ≥50%
(n = 2)
Severity of attacks
improved by <50%
(n = 11)
sE-Selectin 1429.1 1564.4 −135.3 6985.0 .985
sVCAM-1 443639.4 −3122.2 446761.6 119191.6 .003
sICAM-1 27421.2 −6596.9 34018.1 10030.8 .007
MMP-9 31051.5 −19279.3 50330.7 106102.6 .645
tPAI-1 1203.7 −5840.2 7043.9 10808.5 .528
IL-4 0.0 −0.2 0.2 0.4 .689
IL-6 0.0 −1.6 1.6 4.5 .724
IL-8 1.4 −1.2 2.6 2.4 .305
IL-10 0.0 0.0
IL-12p70 −0.1 0.2 −0.3 0.4 .447
IL-17 0.0 −0.3 0.3 0.7 .689
Eotaxin 4.0 −3.3 7.3 12.9 .582
Basic FGF −1.0 2.7 −3.7 3.9 .363
G-CSF 8.8 1.3 7.5 17.7 .680
IFN-γ 9.0 −10.0 19.0 30.2 .542
IP-10 188.5 78.8 109.7 144.4 .463
MCP-1 27.8 −14.7 42.4 11.4 .004
MIP-1α 0.0 0.0 0.0 0.8 .956
MIP-1β 3.1 2.1 1.0 8.8 .916
PDGF-BB 3.0 −218.6 221.6 424.4 .612
TNF-α −0.4 0.7 −1.1 4.2 .798
VEGF 9.5 −3.4 12.9 11.0 .265
TGF-β1 −3.5 −3.1 −0.4 4.1 .919
drug-SJW interactions which were thought to be of clinical
relevance.
AEs were common in this trial, and one SAE in a patient
using SJW occurred. Since our incidence of AEs was fairly
similar in SJW and placebo, many side eﬀects were likely not
related to the study medication.
Patients that reported a >50% improvement in the
frequency of Raynaud’s attacks were associated with higher
levels of the proangiogenic cytokines, MMP-9, MIP-1β,s E -
selectin, G-CSF, and VEGF. Similarly, decreased severity of
these attacks corresponded to increases in plasma levels of
sVCAM-1, sICAM-1, and MCP-1. We did not correct for
multipletests,andsomeofthechangesmaybeduetowithin-
patient variability of the cytokine levels. However, testing
thesecytokinesmaybeusefulinotherproof-of-concepttrials
with diﬀerent agents in RP to determine if any are associated
with clinically relevant RP outcomes.
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